<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487136</url>
  </required_header>
  <id_info>
    <org_study_id>M06-887</org_study_id>
    <nct_id>NCT00487136</nct_id>
  </id_info>
  <brief_title>Interaction Between ABT-335, Rosuvastatin and Warfarin</brief_title>
  <official_title>Multiple-Dose Pharmacokinetic and Pharmacodynamic Interaction Between ABT-335, Rosuvastatin and Warfarin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multiple-dose, double-blind, randomized, single-center, parallel-group study in
      adult male subjects in general good health.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, pharmacodynamic variables</measure>
    <time_frame>Day 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs, physical examinations, laboratory tests, ECGs, adverse events</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin plus ABT-335 plus Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin plus ABT-335 mg plus rosuvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin plus ABT-335 plus rosuvastatin 5 mg</intervention_name>
    <description>Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.</description>
    <arm_group_label>Warfarin plus ABT-335 plus Rosuvastatin</arm_group_label>
    <other_name>warfarin</other_name>
    <other_name>coumadin ABT-335</other_name>
    <other_name>fenofibric acid</other_name>
    <other_name>Trilipix Rosuvastatin</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin plus ABT-335 plus rosuvastatin 20 mg</intervention_name>
    <description>Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.</description>
    <arm_group_label>Warfarin plus ABT-335 mg plus rosuvastatin 20 mg</arm_group_label>
    <other_name>warfarin</other_name>
    <other_name>coumadin</other_name>
    <other_name>ABT-335</other_name>
    <other_name>fenofibric acid</other_name>
    <other_name>Trilipix Rosuvastatin</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) is 19 to 29, inclusive.

          -  A condition of general good health, based upon the results of a medical history,
             physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram
             (ECG).

          -  Written informed consent prior to the initiation of screening or study-specific
             procedures.

        Exclusion Criteria:

          -  Subjects with unstable medical conditions or medical conditions considered
             inappropriate in a clinical trial.

          -  Subjects taking concomitant medications.

          -  Subjects with a recent history of surgery or trauma.

          -  Subjects with a history of any bleeding disorder.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torbjörn Lundström, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Ref # / Investigator 5290</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2007</study_first_posted>
  <last_update_submitted>September 27, 2012</last_update_submitted>
  <last_update_submitted_qc>September 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2012</last_update_posted>
  <responsible_party>
    <name_title>Maureen Kelly, MD</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Drug Interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Fenofibric acid</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

